India's Aurobindo Gets USFDA Nod For Hypertension Drug

Posted AtTradingmarkets.com

Pharmaceutical firm Aurobindo Pharma (BSE:524804) said Thursday it has received tentative approval from US Food and Drug Administration to manufacture and market hypertension drug Losartan Potassium.

The company has received the tentative approval to manufacture and market Losartan Potassium tablets in the strength of 25 mg, 50 mg and 100 mg from USFDA, Aurobindo Phrama said in a filing to the Bombay Stock Exchange.

Losartan Potassium tablets are generic equivalent of Merck Research Laboratories Cozaar tablets of the equal strengths, the company said adding that it is the 75th Abbreviated New Drug Application (ANDA) approval from the US regulator.

The branded sales of Losartan range of products was US$1,235 million, for the year ended December 2007, according to Merck Financial disclosures.

Shares of the company were trading at Rs 306, down 1.18 per cent on BSE in afternoon trade.

August 26, 2008